skip to Main Content

Moving Beyond Chemotherapy in Metastatic Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Chemotherapy regimens continue to dominate the metastatic pancreatic cancer treatment paradigm, but novel combinations with monoclonal antibodies and PARP inhibitors are under investigation in the locally advanced and metastatic settings, respectively, according to Zev A. Wainberg, MD.

“In pancreatic cancer, we are struggling with finding targets of interest and novel drugs beyond chemotherapy that get people excited,” Wainberg said. “We have a lot of work to do to identify the right patients. It is still a chemotherapy-heavy disease so it is going to be tricky [to move beyond this,] but we are trying. Novel immunotherapy targets and approaches are hopefully on the way.” Read more . . . 

 


Back To Top